Pacific Biosciences director proposes $33.1K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pacific Biosciences of California, Inc. (PACB) director Kathy Palmer Ordonez reported a proposed sale of 18,595 common shares, with an approximate sale date of November 17, 2026, and an aggregate market value of $33,093.52. The shares were acquired through restricted stock vesting under a registered plan on February 15, 2022, for services rendered; Morgan Stanley Smith Barney LLC is listed as the broker.
Key Figures
Key Terms
Restricted Stock Vesting Under a Registered Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.